<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70658</article-id><article-id pub-id-type="doi">10.7554/eLife.70658</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand the human ACE2 receptor on binding affinity and kinetics</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-239757"><name><surname>Barton</surname><given-names>Michael I</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9263-6481</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-186946"><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4233-5071</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-141919"><name><surname>Kutuzov</surname><given-names>Mikhail A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3386-4350</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-46608"><name><surname>Dushek</surname><given-names>Omer</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5847-5226</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3241"><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9014-5355</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-59843"><name><surname>van der Merwe</surname><given-names>P Anton</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9902-6590</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Dunn School</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">School of Life Sciences</institution>, <institution>University of Dundee</institution>, <addr-line><named-content content-type="city">Dundee</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Sir William Dunn School of Pathology</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-20368"><name><surname>Fouchier</surname><given-names>Ron AM</given-names></name><role>Reviewing editor</role><aff><institution>Erasmus Medical Center</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>g.j.barton@dundee.ac.uk</email> (GB);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>anton.vandermerwe@path.ox.ac.uk</email> (Pv);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>08</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e70658</elocation-id><history><date date-type="received"><day>25</day><month>05</month><year>2021</year></date><date date-type="accepted"><day>20</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Barton et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Barton et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70658-v1.pdf"/><abstract><p>The interaction between the SARS-CoV-2 virus Spike protein receptor binding domain (RBD) and the ACE2 cell surface protein is required for viral infection of cells. Mutations in the RBD are present in SARS-CoV-2 variants of concern that have emerged independently worldwide. For example, the B.1.1.7 lineage has a mutation (N501Y) in its Spike RBD that enhances binding to ACE2. There are also ACE2 alleles in humans with mutations in the RBD binding site. Here we perform a detailed affinity and kinetics analysis of the effect of five common RBD mutations (K417N, K417T, N501Y, E484K and S477N) and two common ACE2 mutations (S19P and K26R) on the RBD/ACE2 interaction. We analysed the effects of individual RBD mutations, and combinations found in new SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P1) variants. Most of these mutations increased the affinity of the RBD/ACE2 interaction. The exceptions were mutations K417N/T, which decreased the affinity. Taken together with other studies, our results suggest that the N501Y and S477N mutations enhance transmission primarily by enhancing binding, the K417N/T mutations facilitate immune escape, and the E484K mutation enhances binding and immune escape.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>207537/Z/17/Z828</award-id><principal-award-recipient><name><surname>Kutuzov</surname><given-names>Mikhail A</given-names></name><name><surname>Dushek</surname><given-names>Omer</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/J019364/1</award-id><principal-award-recipient><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/R014752/1</award-id><principal-award-recipient><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>101651/Z/13/Z).</award-id><principal-award-recipient><name><surname>MacGowan</surname><given-names>Stuart A</given-names></name><name><surname>Barton</surname><given-names>Geoffrey John</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>P Anton van der Merwe, Own shares in BioNTech SE.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated and analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-70658-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>